AU2005323062A1 - Sustained delivery of PDGF using self-assembling peptide nanofibers - Google Patents

Sustained delivery of PDGF using self-assembling peptide nanofibers Download PDF

Info

Publication number
AU2005323062A1
AU2005323062A1 AU2005323062A AU2005323062A AU2005323062A1 AU 2005323062 A1 AU2005323062 A1 AU 2005323062A1 AU 2005323062 A AU2005323062 A AU 2005323062A AU 2005323062 A AU2005323062 A AU 2005323062A AU 2005323062 A1 AU2005323062 A1 AU 2005323062A1
Authority
AU
Australia
Prior art keywords
seq
peptides
pdgf
self
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005323062A
Other languages
English (en)
Inventor
Patrick Hsieh
Richard T. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2005323062A1 publication Critical patent/AU2005323062A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2005323062A 2005-01-04 2005-12-29 Sustained delivery of PDGF using self-assembling peptide nanofibers Abandoned AU2005323062A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64099805P 2005-01-04 2005-01-04
US60/640,998 2005-01-04
US70231805P 2005-07-26 2005-07-26
US60/702,318 2005-07-26
PCT/US2005/046768 WO2006073889A2 (en) 2005-01-04 2005-12-29 Sustained delivery of pdgf using self-assembling peptide nanofibers

Publications (1)

Publication Number Publication Date
AU2005323062A1 true AU2005323062A1 (en) 2006-07-13

Family

ID=36648006

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005323062A Abandoned AU2005323062A1 (en) 2005-01-04 2005-12-29 Sustained delivery of PDGF using self-assembling peptide nanofibers

Country Status (6)

Country Link
US (1) US7429567B2 (https=)
EP (1) EP1833504A4 (https=)
JP (1) JP2008526749A (https=)
AU (1) AU2005323062A1 (https=)
CA (1) CA2592292A1 (https=)
WO (1) WO2006073889A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031466B1 (en) * 2004-07-06 2018-11-28 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
EP1879606B1 (en) 2005-04-25 2013-06-12 Massachusetts Institute of Technology Self-assembling peptides for promoting hemostasis
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
DK2012842T3 (en) 2006-04-25 2018-05-28 Massachusetts Inst Technology COMPOSITIONS AND PROCEDURES TO INFLUENCE THE MOVEMENT OF CONTAMINANTS, BODIES, OR OTHER UNITS AND / OR TO INFLUENCE OTHER PHYSIOLOGICAL CONDITIONS
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
JP5496671B2 (ja) * 2006-09-26 2014-05-21 マサチューセッツ インスティテュート オブ テクノロジー 修飾自己組織化ペプチド
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
US9012404B2 (en) * 2006-12-11 2015-04-21 3D Matrix, Inc. Compositions and methods for cardiac tissue protection and regeneration
US9415084B2 (en) * 2007-03-14 2016-08-16 Arch Biosurgery, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
KR101670099B1 (ko) 2008-10-06 2016-10-27 가부시끼가이샤 쓰리디 매트릭스 조직 폐색제
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
US20110117195A1 (en) * 2009-11-18 2011-05-19 National Cheng Kung University Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
JP5732691B2 (ja) * 2010-01-14 2015-06-10 学校法人同志社 インスリン製剤
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
RS59080B1 (sr) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antitela protiv antigena 1 povezanog sa bubrezima i njihovi fragmenti koji se vezuju za antigen
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
EP2864353B1 (en) 2012-06-25 2019-03-27 The Brigham and Women's Hospital, Inc. Selective cartilage therapy
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
EP2864360B1 (en) 2012-06-25 2017-09-06 The Brigham and Women's Hospital, Inc. Targeted therapeutics
EP2869903B1 (en) 2012-07-06 2018-11-28 3-D Matrix Ltd. Fill-finish process for peptide solutions
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
US10130735B2 (en) * 2012-09-21 2018-11-20 Technologias Avanzadas Inspiralia S.L. Scaffold for cardiac patch
ES2756531T3 (es) 2013-08-22 2020-04-27 Arch Biosurgery Inc Mallas implantables para controlar el movimiento de fluidos
EP3049054B1 (en) 2013-09-25 2018-04-04 Credentis AG Dental care product for tooth whitening
EP2853256A1 (en) 2013-09-25 2015-04-01 Credentis AG Dental care product for tooth whitening
AU2015229549B2 (en) 2014-03-10 2019-05-23 3-D Matrix, Ltd. Self-assembling peptide compositions
ES2712608T3 (es) 2014-03-10 2019-05-14 3 D Matrix Ltd Péptidos autoensamblantes para el tratamiento de las bullas pulmonares
WO2015136370A2 (en) 2014-03-10 2015-09-17 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
CN104497107B (zh) * 2014-12-08 2017-09-19 重庆医科大学 一种自组装短肽及其在细胞三维培养中的应用
CN104693277B (zh) * 2015-03-26 2018-02-13 罗忠礼 一种自组装短肽及其在细胞三维培养中的应用
CN105148289B (zh) * 2015-09-30 2018-10-09 南京中医药大学 一种两亲性寡聚多肽药物结合物
CN105288653B (zh) * 2015-11-19 2018-10-09 南京中医药大学 一种两亲性寡聚多肽药物结合物
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
EP3248591A1 (en) 2016-05-24 2017-11-29 Credentis AG Method and product for caries treatment
EP3248590A1 (en) 2016-05-24 2017-11-29 Credentis AG Personal dental care product for caries treatment
CN117085140A (zh) 2017-12-15 2023-11-21 立美基股份有限公司 表面活性剂肽纳米结构及在药物递送中的用途
WO2020171161A1 (ja) * 2019-02-20 2020-08-27 国立大学法人東京農工大学 自己組織化ペプチド
EP3831360A1 (en) 2019-12-04 2021-06-09 Credentis AG Personal dental care product for preventing demineralisation
US11154470B1 (en) 2020-07-31 2021-10-26 vVardis AG Anti-inflammatory and senolytic dental care product with tooth whitening characteristics
CN114181295B (zh) * 2021-12-15 2023-07-04 湖南大学 一种多肽衍生物及其用途、水凝胶及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US6086866A (en) * 1993-04-29 2000-07-11 Kouri; Roger Khalil Use of platelet-derived growth factor to improve collateral circulation
CA2222550A1 (en) * 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
WO2001035932A2 (en) * 1999-11-18 2001-05-25 The Regents Of The University Of Michigan Sustained drug delivery from structural matrices
US7449180B2 (en) 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
EP1367961B1 (en) * 2001-02-06 2008-12-31 Massachusetts Institute Of Technology Peptide scaffold encapsulation of tissue cells and uses thereof
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
WO2003006043A1 (en) * 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
KR20030043780A (ko) 2001-11-28 2003-06-02 주식회사 바이오폴리메드 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법
US20030139333A1 (en) * 2002-01-18 2003-07-24 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis
WO2003096972A2 (en) * 2002-05-13 2003-11-27 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
WO2004007683A2 (en) * 2002-07-15 2004-01-22 Massachusetts Institute Of Technology Cellular reprogramming in peptide hydrogel and uses thereof
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
WO2004045531A2 (en) * 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005014615A2 (en) * 2003-06-25 2005-02-17 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
EP3031466B1 (en) * 2004-07-06 2018-11-28 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof

Also Published As

Publication number Publication date
JP2008526749A (ja) 2008-07-24
US20060148703A1 (en) 2006-07-06
WO2006073889A3 (en) 2007-06-14
EP1833504A2 (en) 2007-09-19
WO2006073889A2 (en) 2006-07-13
US7429567B2 (en) 2008-09-30
EP1833504A4 (en) 2009-08-12
CA2592292A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
US7429567B2 (en) Sustained delivery of PDGF using self-assembling peptide nanofibers
Liu et al. A self-assembling peptide hydrogel-based drug co-delivery platform to improve tissue repair after ischemia-reperfusion injury
Wu et al. An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques
Jia et al. Cardiovascular effects of a PEGylated apelin
EP2076290B1 (en) Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US7399831B2 (en) Targeted delivery of biological factors using self-assembling peptide nanofibers
US20110117195A1 (en) Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
EP3867648A1 (en) Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis
CN110603260B (zh) Npra激动剂、组合物及其用途
Wang et al. Cascaded bio-responsive delivery of eNOS gene and ZNF 580 gene to collaboratively treat hindlimb ischemia via pro-angiogenesis and anti-inflammation
KR20180119697A (ko) 세포자멸사의 억제제 및 이의 용도
US20190216956A1 (en) Compositions for radiotherapy and uses thereof
AU2006308989A1 (en) Novel protein transduction domains and uses therefor
AU2026201537A1 (en) Alginate-based microcapsulation for the delivery of alpha-CGRP in cardiovascular diseases
US20240197896A1 (en) Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery
WO2003080103A1 (en) Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
JP2025534734A (ja) 心筋細胞を保存及び保護し、心損傷後の心筋線維化を軽減する方法
US20220257711A1 (en) PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES
EP3490615A1 (en) Gel-bound compositions for radiotherapy and uses thereof
Zhao et al. Salvianolic acid B, a novel GLS1 accelerator, alleviates defective endothelial glutaminolysis contributes to impaired angiogenesis and poor ischemic tissue repair in diabetes
CN120983639A (zh) 一种基于多肽修饰的寡核苷酸纳米递送体系及其应用
US20210236668A1 (en) Compositions for radiotherapy and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application